Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 666.2 million compared to INR 600.51 million a year ago. Revenue was INR 681.07 million compared to INR 606.06 million a year ago. Net income was INR 71.9 million compared to INR 83.73 million a year ago. Basic earnings per share from continuing operations was INR 5.68 compared to INR 6.85 a year ago. Diluted earnings per share from continuing operations was INR 5.68 compared to INR 6.85 a year ago.